| abstract |
1,2-Di-substituted heterocyclic compounds are described, which are phosphodiesterase 10 inhibitors. Methods, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including humans, for system disorders are also described. central nervous (CNS) and other disorders that can affect the function of the CNS. Among the disorders that can be treated are neurological, neurodegenerative and psychiatric disorders, including, but not limited to those associated with cognitive deficits or schizophrenic symptoms. |